Consortium raises €20m Series C for Affimed

Affimed Therapeutics AG develops antibody therapeutics as treatments for life threatening diseases with unmet medical need.

The company has been generating a pipeline of anticancer drug candidates based on its proprietary TandAb technology platform.

Affimed's lead product candidate AFM13 for the treatment of Hodgkin's disease has completed preclinical development and will enter clinical studies in the third quarter of 2010. Both AFM11 and AFM12 to treat Non-Hodgkin's lymphoma are currently in preclinical development and are expected to begin clinical studies in 2011.

Further novel product candidates are being developed for the treatment of solid tumors, autoimmune diseases and asthma.

Affimed, which employs 26 people in Heidelberg, is a spin-off from the German Cancer Research Centre (DKFZ).

 

• Tweet  
• Facebook  
• LinkedIn  
• Google plus  
• Send to  

• Topics
• DACH
• Healthcare
• Early-stage
• Germany
• Index Ventures